The First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2023 Aug 2;18:1681-1690. doi: 10.2147/COPD.S412626. eCollection 2023.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by neutrophils airway infiltration. It is currently known that Interleukin-17 (IL-17) is an important pro-inflammatory factor. It can promote the accumulation of neutrophils and participate in the chronic inflammatory process of COPD. However, the value of IL-17 levels in the diagnosis and assessment of COPD remains controversial. In view of this, we conducted a systematic review and meta-analysis to assess its relevance.
We searched databases such as PubMed, Web of Science, Cochrane Library and Embase to extract original research.
A total of 10 studies with 2268 participants were included in this meta-analysis. The results showed that the level of serum IL-17 in patients with stable COPD was significantly higher than that in healthy controls (standard mean difference SMD, 1.59, 95% CI 0.84-2.34; <0.001). Compared with the stable COPD group, the serum IL-17 level in acute exacerbation (AECOPD) was significantly higher (SMD, 1.78, 95% CI 1.22-2.33; <0.001). The level of IL-17 in sputum of COPD patients was also higher than that of healthy controls (SMD, 2.03, 95% CI 0.74-3.31; <0.001).
Our results showed that IL-17 levels were elevated in serum and sputum in COPD patients compared with healthy controls, and IL-17 levels increased with disease progression. IL-17 serves as a potential biomarker to indicate the persistence of neutrophilic inflammation and exacerbation of COPD.
慢性阻塞性肺疾病（COPD）是一种以中性粒细胞气道浸润为特征的慢性炎症性疾病。目前已知白细胞介素-17（IL-17）是一种重要的促炎因子。它可以促进中性粒细胞的积累，并参与 COPD 的慢性炎症过程。然而，IL-17 水平在 COPD 的诊断和评估中的价值仍存在争议。鉴于此，我们进行了系统评价和荟萃分析以评估其相关性。
我们检索了 PubMed、Web of Science、Cochrane 图书馆和 Embase 等数据库，以提取原始研究。
共有 10 项研究，2268 名参与者纳入本荟萃分析。结果表明，稳定期 COPD 患者的血清 IL-17 水平明显高于健康对照组（标准均数差 SMD，1.59，95%置信区间 0.84-2.34；<0.001）。与稳定期 COPD 组相比，急性加重期（AECOPD）的血清 IL-17 水平明显升高（SMD，1.78，95%置信区间 1.22-2.33；<0.001）。COPD 患者的痰中 IL-17 水平也高于健康对照组（SMD，2.03，95%置信区间 0.74-3.31；<0.001）。
我们的结果表明，与健康对照组相比，COPD 患者的血清和痰中 IL-17 水平升高，且随着疾病的进展，IL-17 水平升高。IL-17 可作为指示中性粒细胞炎症持续存在和 COPD 加重的潜在生物标志物。
